Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Turcot syndrome 1Medulloblastoma 1Gliosarcoma 1Glioma 1Glioblastoma 1Familial ependymoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Brain Neoplasms 1

Interventions

Temozolomide 6O(6)-benzylguanine 3Magnetic Resonance Spectroscopy 3Filgrastim 3Vorinostat 2Specimen Handling 2Radiotherapy 2Oxaliplatin 2Irinotecan 2Erlotinib Hydrochloride 2Carboplatin 2veliparib 1sargramostim 1romidepsin 1phenylacetic acid 1pembrolizumab 1palbociclib 1olaparib 1ixabepilone 1ispinesib 1erdafitinib 1cediranib 1becatecarin 1alvocidib 1X-Rays 1Verteporfin 1Thiotepa 1Tamoxifen 1Sunitinib 1RMP 7 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Familial ependymoma × Diffusion Tensor Imaging × Clear all
NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
71 enrolled
CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡